Vyome Holdings, Inc. (Nasdaq: HIND) (“Vyome”), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for U.S. Patent Application No. 17/787,303, titled “Formulations and Method for Treatment of Inflammatory Diseases.”

The USPTO has allowed the multiple claims filed under the above application number covering formulations and methods of use underlying Vyome’s VT-1908 program.

VT-1908 is Vyome’s novel topical ophthalmic formulation of mycophenolate being developed initially for anterior uveitis, with a longer-term opportunity to address a broader range of ocular and periocular inflammatory conditions where steroid-sparing or steroid-replacement therapies are needed. Vyome has previously estimated from public sources the broader global addressable market for ocular inflammation at more than $20 billion by 20351. Potential indications include uveitis, post-operative ocular inflammation, scleritis, blepharitis, dry eye, and other inflammatory conditions of the eye.

The scientific foundation for VT-1908 has already undergone peer review. Preclinical results were published in February 2026 in the Journal of Ophthalmic Inflammation and Infection, a Springer Nature journal, in the paper “Topical mycophenolate for the treatment of uveitis-associated inflammation2.” The study demonstrated that topical mycophenolate achieved therapeutic ocular concentrations, significantly reduced inflammation in a preclinical uveitis model, and showed efficacy comparable to topical steroid treatment.

Venkat Nelabhotla, CEO of Vyome, stated, “We believe this Notice of Allowance significantly strengthens the intellectual property foundation around VT-1908. While uveitis is our initial development focus, our longer-term vision is much broader. Topical steroids are extensively used across ocular inflammatory conditions, and there remains a significant need for effective steroid-sparing alternatives. We believe VT-1908 has the potential to address this broader need across an ocular inflammation market opportunity exceeding $20 billion. With strong intellectual property and peer-reviewed scientific validation, we believe VT-1908 represents an important additional value driver within Vyome’s immuno-inflammatory pipeline.”

Dr. Shiladitya Sengupta, Associate Professor of Medicine at Harvard Medical School and Co-Founder of Vyome, said, “Mycophenolate is a well-established immunomodulator, but delivering it effectively as a topical ophthalmic therapy required solving significant formulation and drug-delivery challenges. Our published preclinical work demonstrated that topical VT-1908 can potentially achieve the desired ocular exposure and produce anti-inflammatory efficacy comparable to a steroid in the uveitis model. The USPTO Notice of Allowance further validates the novelty of the formulation and methods underlying this approach and supports our broader scientific objective of developing a non-steroidal alternative for inflammatory diseases of the eye.”

About VT-1908

VT-1908 is Vyome’s investigational topical ophthalmic formulation of mycophenolate being developed as a potential steroid-sparing treatment for anterior uveitis. Preclinical studies have demonstrated anti-inflammatory activity following topical ocular administration, supporting continued development of VT-1908 as a potential non-steroidal therapeutic approach for patients with anterior uveitis.

About Vyome Holdings, Inc.

Vyome is building the world’s premier platform spanning the US-India innovation corridor. Based in Cambridge, MA, Vyome’s immediate focus is on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. By applying groundbreaking science and its unique positioning, Vyome seeks to deliver lasting value to shareholders in a cost-efficient manner while upholding global standards of quality and safety. To learn more, please visit www.vyometx.com.

Forward-Looking Statements

Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “target,” “believe,” “expect,” “will,” “shall,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” “forecast,” “intend,” “plan,” “project,” “outlook,” “potential,” “vision,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such statements include, but are not limited to, statements contained in this press release relating to Vyome’s business strategy, including the expected issuance of a U.S. patent following the USPTO Notice of Allowance and the scope and strength of the intellectual property protection it may provide; the development plans for VT-1908, including any potential expansion into new ocular and periocular inflammatory indications; the estimated size of the addressable ocular inflammation market; and VT-1908’s potential to serve as a value driver within Vyome’s immuno-inflammatory pipeline. Forward-looking statements are based on Vyome’s current expectations and assumptions regarding Vyome’s business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Vyome’s actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. Vyome cautions you, therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, the possibility that the patent does not issue as expected or that any issued patent is challenged, invalidated, narrowed or circumvented; Vyome’s ability to protect Vyome’s intellectual property rights; the impact of any infringement actions or other litigation brought against Vyome; the timing, cost and outcome of preclinical and clinical development of VT-1908; Vyome’s ability to obtain regulatory approval for VT-1908 or any other product candidate; the accuracy of Vyome’s market size estimates and assumptions; competition from other providers and products; Vyome’s ability to develop and commercialize products and services; changes in government regulation; Vyome’s ability to complete capital raising transactions and obtain sufficient funding for its development programs; and other factors relating to Vyome’s industry, operations and results of operations, including those discussed under “Risk Factors” in Vyome’s most recent Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Factors or events that could cause Vyome’s actual results to differ may emerge from time to time, and it is not possible for Vyome to predict all of them. Vyome cannot guarantee future results, levels of activity, performance, or achievements. Vyome assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release, except as may be required under applicable securities law.

1 https://www.imarcgroup.com/uveitis-treatment-market

https://www.databridgemarketresearch.com/reports/global-scleritis-market

Fortune Business Insights – Dry Eye Syndrome Market

https://www.futuremarketinsights.com/reports/post-operative-cataract-surgery-inflammation-market

Business Research Insights – Blepharitis Market Report

2 https://link.springer.com/article/10.1186/s12348-026-00569-y

Media gallery

About The Author
Business Wire